Meta Health Limited, a Singapore-based healthcare company, has announced its proposed renounceable, non-underwritten rights issue offering of up to 264,078,029 new ordinary shares. This development, aimed at raising additional capital, is expected to have significant implications for shareholders and potential investors. Detailed below are the key highlights and critical information that shareholders need to know.

Key Highlights of the Rights Issue

• Rights Issue Structure: The offer is a renounceable, non-underwritten rights issue, allowing eligible shareholders to purchase additional shares at a predetermined price. This move is intended to raise funds for the company’s operations and strategic initiatives.
• Electronic Dissemination of Offer Information Statement: The Offer Information Statement (OIS) was lodged on 20 January 2025 and is available electronically on the company’s website and the SGXNet platform. No physical copies will be sent to shareholders.
• Offer Timeline: Key dates for the rights issue include:
  • Commencement of trading of Nil-Paid Rights: 22 January 2025, 9:00 AM
  • Last date for trading of Nil-Paid Rights: 3 February 2025, 5:00 PM
  • Last date for acceptance and payment for Rights Shares: 7 February 2025, 5:30 PM (9:30 PM for electronic applications)
  • Expected allotment and issuance of Rights Shares: 13 February 2025
  • Expected listing date for Rights Shares: 17 February 2025
• Who Can Participate: The rights issue is available to shareholders with registered addresses in Singapore. Foreign shareholders or purchasers based outside Singapore are excluded due to regulatory constraints.
• Application Methods: Shareholders can accept their provisional allotments and apply for excess shares via:
  • Physical Application Form (ARE)
  • Electronic Applications through ATMs of participating banks
  • Other approved services for CPFIS and SRS investors
• Critical Notes on Excess Rights Shares: Only entitled shareholders (not purchasers or renouncees) can apply for excess Rights Shares beyond their provisional allotments.

Potential Price-Sensitive Information

The announcement of the rights issue may impact the share price of Meta Health Limited for the following reasons:

• Capital Dilution: With the issuance of up to 264,078,029 new shares, the existing shareholding structure will experience dilution. This could potentially pressure the share price downward in the short term.
• Strategic Fundraising: The raised capital may be used for growth initiatives, expansion, or debt reduction, which could positively influence the company’s financial health and long-term share valuation.
• Market Demand for Rights Shares: The trading period for Nil-Paid Rights (22 January 2025–3 February 2025) will be crucial in determining market confidence and interest in the company’s future prospects.

Important Instructions for Shareholders

Shareholders are strongly advised to take note of the following:

• Ensure that all applications for rights shares or excess rights shares are made through the appropriate channels. Direct submissions to CDP, the Share Registrar, or the company will be rejected.
• Investors holding shares under CPFIS, SRS, or through finance companies/depository agents must coordinate with their respective intermediaries.
• Foreign shareholders and purchasers outside Singapore must consult their brokers or agents, as participation may be restricted under local laws.
• Stay informed of updates on the rights issue via SGXNet or the company’s website.

Indicative Timetable of Key Events